Company: BIAF
Filing Date: 2025-05-02
Form Type: S-1
Source: 0001641172-25-008170
Chunk: 140

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-05-02
Form: S-1
Chunk 140
---
 and settlement costs, diversion of resources, and other factors. Results of actual and potential litigation are inherently uncertain, and there can be no assurances that favorable outcomes will be obtained.

Implications of Being an Emerging Growth Company and a Smaller Reporting Company

We qualify as an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. For as long as we remain an emerging growth company, we may take advantage of specified reduced reporting requirements and other burdens that are otherwise applicable generally to other public companies. These provisions include, but are not limited to:

| ● | reduced                                                                                                                                
 obligations with respect to financial data, including presenting only two years of audited financial statements and selected financial 
 data, and only two years of related Management’s Discussion and Analysis of Financial Condition and Results of Operations disclosure   
 in our initial registration statement;                                                                                                 |
| ● | an                                                                                                                                     
 exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting pursuant to      
 the Sarbanes-Oxley Act of 2002, as amended (“SOX”);                                                                                    |
| ● | reduced                                                                                                                                
 disclosure about executive compensation arrangements in our periodic reports, registration statements, and proxy statements; and       |
| ● | exemptions                                                                                                                             
 from the requirements to seek non-binding advisory votes on executive compensation or stockholder approval of any golden parachute     
 arrangements.                                                                                                                          |

| 63 |

We may take advantage of some or all of these provisions until we are no longer an emerging growth company. We will remain an emerging growth company until the earliest of (1) the last day of the fiscal year following the fifth anniversary of the completion of our initial public offering, (2) the last day of the first fiscal year in which our annual gross revenues exceed $1.235 billion, (3) the date on which we have, during the immediately preceding three-year period, issued more than $1.0 billion in non-convertible debt securities and (4) the date on which we are deemed to be a large accelerated filer under the rules of the SEC. We may choose to take advantage of some but not all of these reduced burdens. For example, we have taken advantage of the reduced reporting requirements with respect to disclosure regarding our executive compensation arrangements, have presented only two years of audited financial statements and only two years of related “Management’s Discussion and Analysis of Financial Condition and Results of Operations” disclosure in this prospectus, and have taken advantage of the exemption